2014 News Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
08/07/14Verastem Reports Second Quarter 2014 Financial and Corporate Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 7, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, reported financial results for the second quarter ended June 30, 2014, and also provided an overview of certain corporate accomplishments and plans. “We ended the second quarter with a cash, cash equivalents and investments balance of $104.4 million which w... 
Printer Friendly Version
07/10/14Verastem Presents Results and Updated Development Plans at Annual Research and Development Day
-Lead cancer stem cell inhibitor VS-6063 continues to show promise in the clinic- -An additional partial response reported since ASCO in the combination trial of VS-6063 and paclitaxel in ovarian cancer- -64% stable disease or better as best clinical response to date, including five objective responses, in the ongoing combination trial of VS-6063 and paclitaxel in ovarian cancer- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 10, 2014... 
Printer Friendly Version
07/08/14Verastem to Ring the NASDAQ Stock Market Closing Bell and Host Annual Research and Development Day on July 10, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 8, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that it will ring the Closing Bell at the NASDAQ MarketSite in Times Square, New York City, on Thursday, July 10, 2014, at 4:00 p.m. ET. The Closing Bell ceremony will take place immediately following the conclusion of the Company’s annual Research and D... 
Printer Friendly Version
06/24/14Verastem’s Published Scientific Data on Targeting Mesothelioma Cancer Stem Cells Receives Coverage in AACR’s Cancer Discovery
- The Registration-Directed COMMAND Study of VS-6063 for Patients with Malignant Pleural Mesothelioma to be Highlighted at the Company’s Upcoming R&D Day on July 10 - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 24, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced publication of an article titled “FAK Inhibitor Kills Mesothelioma Cells” in ... 
Printer Friendly Version
06/18/14Verastem Announces Annual Research and Development Day and Webcast
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 18, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the Company will host its annual Research and Development Day on Thursday, July 10, 2014 from 12:30 – 4:00pm ET at The Hudson Theatre at the Millennium Broadway Hotel in New York City. The Company will provide updates regarding its research a... 
Printer Friendly Version
06/10/14Verastem to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 10, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will participate at several upcoming conferences. The presentation details are as follows: 2014 Wells Fargo Healthcare Conference on Tuesday, June 17, 2014 at 3:30 p.m. ET at The InterContinental Hotel in Boston, MA ... 
Printer Friendly Version
06/02/14Verastem Presents Updated Clinical Data from VS-6063 and Paclitaxel Combination Phase 1/1b Study in Patients with Ovarian Cancer at the 2014 ASCO Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 2, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the presentation of clinical data in a poster presentation and discussion at the American Society of Clinical Oncology Annual Meeting being held May 30 – June 3, 2014, at McCormick Place in Chicago, IL. Verastem presented interim data from the ongoing Ph... 
Printer Friendly Version
05/27/14Verastem Publishes Scientific Data on Targeting Mesothelioma Cancer Stem Cells in Science Translational Medicine
- Study Demonstrates Increased Efficacy of FAK Inhibition in Pre-clinical Models of Merlin-negative Mesothelioma - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 27, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that a paper, entitled “Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship,” has been published... 
Printer Friendly Version
05/20/14Verastem to Present at the 2014 ASCO Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 20, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced scheduled poster presentations at the American Society of Clinical Oncology Annual Meeting being held May 30 – June 3, 2014, at McCormick Place in Chicago, IL. Interim data from the ongoing Phase 1/1b trial of lead candidate targeting cancer stem ... 
Printer Friendly Version
05/14/14Verastem to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 14, 2014-- Verastem, Inc., (NASDAQ:VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at upcoming investor conferences. The presentation details are as follows: UBS Global Healthcare Conference on Monday, May 19, 2014, at 3:30 p.m. ET at the Sheraton New York Hotel in New ... 
Printer Friendly Version
05/12/14Verastem Announces Initiation of COMMAND Study in Japan
Japanese Investigative Sites Join International Trial of VS-6063 for Patients with Mesothelioma — Allowance by the PMDA Enables Verastem to Pursue Parallel Development in the Major Markets Worldwide – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 12, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the expansion ... 
Printer Friendly Version
05/12/14Dr. Paul A. Friedman Joins Verastem Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 12, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the appointment of Paul A. Friedman, M.D. to its Board of Directors. “We are delighted to welcome Paul to the Verastem Board of Directors,” said Christoph Westphal, M.D., Ph.D., Verastem Executive Chairman. “Paul has significant development ... 
Printer Friendly Version
05/08/14Verastem Reports First Quarter 2014 Financial and Corporate Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 8, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the first quarter ended March 31, 2014, and also provided an update of certain corporate accomplishments and plans. “We continue to advance our development programs targeting cancer stem cells,” said Robert Forrester, Pre... 
Printer Friendly Version
04/30/14Verastem to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 30, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will participate at several upcoming conferences. The presentation details are as follows: Deutsche Bank 39th Annual Healthcare Conference on Wednesday, May 7, 2014 at 9:20 a.m. ET at The InterContinental Hotel ... 
Printer Friendly Version
04/09/14Verastem Presents Data on Cancer Stem Cell-Targeting Agents at the 2014 AACR Annual Meeting
- Research Results Provide Additional Support for Targeting Cancer Stem Cells Directly and Through Immunomodulation of the Tumor Microenvironment – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 9, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the presentation of scientific data at the American Association for Cancer Research annual meetin... 
Printer Friendly Version
03/25/14Verastem to Present Data on Product Candidates Targeting Cancer Stem Cells at the American Association of Cancer Research Meeting
-New research to be presented in an oral session and three poster presentations- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 25, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present data at the upcoming American Association of Cancer Research (AACR) meeting to be held April 5-9, 2014 at the San Diego Convention Center i... 
Printer Friendly Version
03/20/14Verastem to Present at the Boston Business Development Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 20, 2014-- Verastem, Inc., (NASDAQ:VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be participating in the upcoming Boston Business Development Conference on Tuesday and Wednesday, March 25-26, 2014. The conference will take place at The Four Seasons Hotel in Boston. About Verastem, Inc.... 
Printer Friendly Version
03/11/14Timothy J. Barberich Joins Verastem Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 11, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the appointment of Timothy J. Barberich to its Board of Directors. “Tim is an entrepreneur at heart who has become a very successful biopharmaceutical business leader,” said Christoph Westphal, M.D., Ph.D., Verastem Executive Chairman. “As ... 
Printer Friendly Version
03/06/14Verastem Reports Year-End 2013 Financial Results
--A year of clinical execution: Three small molecule compounds in clinical development including the registration-directed COMMAND study— --Multiple clinical data readouts anticipated starting in first half 2014-- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2014-- Verastem, Inc., (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for t... 
Printer Friendly Version
03/05/14Verastem Reports Data from Phase 1 Study of VS-6063 (defactinib) in Japanese Patients
– Well Tolerated; Meets Study Objectives – – Results Facilitate Potential Parallel Development of VS-6063 (defactinib) in Japan – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2014-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today presented preliminary data from an ongoing First-in-Asia Phase 1 trial of VS-6063 in Japanese patients with advanced... 
Printer Friendly Version
03/04/14Verastem to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 4, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present at upcoming investor conferences. The presentation details are as follows: 26th Annual Roth Conference on Monday, March 10th at 11:30 a.m. PT at The Ritz Carlton in Dana Point, CA Barclay... 
Printer Friendly Version
02/28/14Verastem Supports Worldwide Rare Disease Day on February 28, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 28, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced its support of the rare disease awareness events being held globally. Verastem’s lead compound targeting cancer stem cells, VS-6063, is currently in the registration-directed COMMAND study and has been granted orphan drug designation in the U.S. and E.U. ... 
Printer Friendly Version
02/26/14Verastem to Present at Upcoming Scientific Conferences
-Results from a Phase 1 study of VS-6063 in Japanese patients to be announced- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 26, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present at two upcoming scientific conferences, including the 12th International Congress on Targeted Anticancer Therapies (TAT), where a poster with... 
Printer Friendly Version
02/25/14Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718
--The acquisition reduces milestones and royalties associated with ongoing VS-4718 development-- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it has acquired the license to VS-4718 held originally by Poniard Pharmaceuticals. The previous and future developmental, regulatory and comme... 
Printer Friendly Version
02/24/14Cancer Research Publication Highlights Importance of Merlin Loss and Cancer Stem Cells in Mesothelioma
Research Demonstrates Cooperativity between Loss of Merlin and p16/ARF in Driving the Development of Highly Aggressive Disease In Vivo CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 24, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that a publication in the journal Cancer Research supports the scientific rationale for the Company’s ongoing ... 
Printer Friendly Version
02/19/14Verastem to Host Conference Call on March 6th to Discuss Year-End 2013 Financial Results and Recent Highlights
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 19, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will host a conference call on Thursday, March 6, 2014 at 8:00 a.m. Eastern Time to discuss corporate updates and financial results for the year ended December 31, 2013. The call can be accessed by dialing (866) 953-6857 (U.S. and Canad... 
Printer Friendly Version
02/10/14Nature Immunology Paper Highlights Potential Role of FAK Inhibition in Hematological Malignancies
Research from UC Irvine, Massachusetts General Hospital and Tufts Medical Center Points to Potential Development of Verastem FAK inhibitors in subset of Acute Lymphoblastic Leukemia CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that a publication in Nature Immunology demonstrates the scien... 
Printer Friendly Version
02/06/14Verastem to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present at upcoming scientific and investor conferences. The presentation details are as follows: 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 3:00 p.m. ET at the Waldorf Astoria in New ... 
Printer Friendly Version
02/04/14Verastem Issued Japanese Patent on Dual mTORC1/2 and PI3K Inhibitor VS-5584
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 4, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it has been issued a patent by the Japanese Patent Office (JPO) for the company’s small molecule dual inhibitor of mTORC1/2 and PI3K VS-5584. The granted patent is titled “Pyrimidine Substituted Purine Compounds As Kinase(s) Inhibitors,” and has claim... 
Printer Friendly Version